Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Core Insights - The U.S. FDA has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [1] - FCS is a severe and rare disease affecting an estimated 6,500 individuals in the U.S., characterized by extremely high triglyceride levels [1] Company Summary - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is the company behind the newly approved siRNA medicine [1] - The approval of REDEMPLO represents a significant advancement in treatment options for patients suffering from FCS [1] Industry Context - The approval of siRNA therapies like REDEMPLO highlights the growing importance of RNA-based treatments in addressing rare genetic disorders [1] - The market for treatments targeting rare diseases is expanding, driven by increasing awareness and advancements in biotechnology [1]